Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Says Bexmarilimab study shows 50% remission rate for patients with in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Says eight of eleven patients were complete responders or complete responders with incomplete blood recovery. Adds Bexmarilimab continues to be well-tolerated at all tested dose levels, as no dose-limiting toxicity has been observed.

Chief Executive Officer Markku Jalkanen says: ‘The emerging data from Phase 1/2 continue to be extremely promising, showing continued good safety, encouraging efficacy and long durations of response.

‘We believe that Bexmarilimab has the potential to provide better patient outcomes and improve the quality of life of those suffering from relapsed/refractory AML and MDS, which are conditions with dire prognosis and limited new therapies in the last decades.’

Current stock price: 330.20 pence, down 5.7%

12-month change: up 89%

Copyright 2023 Alliance News Ltd. All Rights Reserved.